BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hellmann J, Drabek M, Yin J, Gunera J, Pröll T, Kraus F, Langmead CJ, Hübner H, Weikert D, Kolb P, Rosenbaum DM, Gmeiner P. Structure-based development of a subtype-selective orexin 1 receptor antagonist. Proc Natl Acad Sci U S A 2020;117:18059-67. [PMID: 32669442 DOI: 10.1073/pnas.2002704117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Paggi JM, Belk JA, Hollingsworth SA, Villanueva N, Powers AS, Clark MJ, Chemparathy AG, Tynan JE, Lau TK, Sunahara RK, Dror RO. Leveraging nonstructural data to predict structures and affinities of protein-ligand complexes. Proc Natl Acad Sci U S A 2021;118:e2112621118. [PMID: 34921117 DOI: 10.1073/pnas.2112621118] [Reference Citation Analysis]
2 Selvaraj S, Rodrigues D, Krishnamoorthy N, Fakhro KA, Saraiva LR, Lemos MC. Clinical, Genetic and Functional Characterization of a Novel AVPR2 Missense Mutation in a Woman with X-Linked Recessive Nephrogenic Diabetes Insipidus. JPM 2022;12:118. [DOI: 10.3390/jpm12010118] [Reference Citation Analysis]
3 Alain C, Pascal N, Valérie G, Thierry V. Orexins/Hypocretins and Cancer: A Neuropeptide as Emerging Target. Molecules 2021;26:4849. [PMID: 34443437 DOI: 10.3390/molecules26164849] [Reference Citation Analysis]
4 Gunera J, Baker JG, van Hilten N, Rosenbaum DM, Kolb P. Structure-Based Discovery of Novel Ligands for the Orexin 2 Receptor. J Med Chem 2020;63:11045-53. [PMID: 32977721 DOI: 10.1021/acs.jmedchem.0c00964] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Gulezian E, Crivello C, Bednenko J, Zafra C, Zhang Y, Colussi P, Hussain S. Membrane protein production and formulation for drug discovery. Trends Pharmacol Sci 2021;42:657-74. [PMID: 34270922 DOI: 10.1016/j.tips.2021.05.006] [Reference Citation Analysis]
6 Sun Y, Tisdale RK, Kilduff TS. Hypocretin/Orexin Receptor Pharmacology and Sleep Phases. Front Neurol Neurosci 2021;45:22-37. [PMID: 34052813 DOI: 10.1159/000514963] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Jacobson LH, Hoyer D, de Lecea L. Hypocretins (orexins): The ultimate translational neuropeptides. J Intern Med 2022. [PMID: 35043499 DOI: 10.1111/joim.13406] [Reference Citation Analysis]
8 Tropmann K, Bresinsky M, Forster L, Mönnich D, Buschauer A, Wittmann HJ, Hübner H, Gmeiner P, Pockes S, Strasser A. Abolishing Dopamine D2long/D3 Receptor Affinity of Subtype-Selective Carbamoylguanidine-Type Histamine H2 Receptor Agonists. J Med Chem 2021;64:8684-709. [PMID: 34110814 DOI: 10.1021/acs.jmedchem.1c00692] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Cai X, Wang H, Wang M, Wang D, Zhang Z, Wei R, Gao X, Zhang R, Wang C, Chen J. A novel phosphorylation site on orexin receptor 1 regulating orexinA-induced GRK2-biased signaling. Cell Signal 2020;75:109743. [PMID: 32827691 DOI: 10.1016/j.cellsig.2020.109743] [Reference Citation Analysis]
10 Ballante F, Kooistra AJ, Kampen S, de Graaf C, Carlsson J. Structure-Based Virtual Screening for Ligands of G Protein-Coupled Receptors: What Can Molecular Docking Do for You? Pharmacol Rev 2021;73:527-65. [PMID: 34907092 DOI: 10.1124/pharmrev.120.000246] [Reference Citation Analysis]
11 Kricker JA, Page CP, Gardarsson FR, Baldursson O, Gudjonsson T, Parnham MJ. Nonantimicrobial Actions of Macrolides: Overview and Perspectives for Future Development. Pharmacol Rev 2021;73:233-62. [PMID: 34716226 DOI: 10.1124/pharmrev.121.000300] [Reference Citation Analysis]
12 Wiseman DN, Samra N, Román Lara MM, Penrice SC, Goddard AD. The Novel Application of Geometric Morphometrics with Principal Component Analysis to Existing G Protein-Coupled Receptor (GPCR) Structures. Pharmaceuticals (Basel) 2021;14:953. [PMID: 34681177 DOI: 10.3390/ph14100953] [Reference Citation Analysis]